1 / 36

Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cereb

Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral Ischemia. Rapid TIA Patient Evaluation and Treatment: Lessons Learned from FASTER, EXPRESS, and SOS-TIA. TIA – is it an emergency?.

thimba
Télécharger la présentation

Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cereb

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral Ischemia

  2. Rapid TIA Patient Evaluation and Treatment: Lessons Learned from FASTER, EXPRESS, and SOS-TIA

  3. TIA –is it an emergency? What is the optimal management of ED patients with suspected cerebral ischemia?

  4. Jonathan A. Edlow, MDVice-chairmanDepartment of Emergency MedicineBeth Israel Deaconess Medical CenterAssociate Professor of MedicineHarvard Medical SchoolBoston, MA

  5. Disclosures • Dr. Edlow is a member of the ACEP Clinical Policies committee

  6. Session Objectives • Evaluate which therapies might be initiated for ED TIA patients in order to minimize the subsequent stroke risk and maximize patient outcome.

  7. Treatment • Should I start an anti-platelet drug? If so, which one? • Is there a significant carotid stenosis? How is this best treated? • Is there atrial fibrillation or other cardio-embolic sources of the TIA?

  8. Anti-platelet therapyAHA guidelines - 2006 • ASA – dose 50-325mg • ASA plus extended release dipyridamole (50-400mg) • Clopidogrel (75mg)

  9. CASTIA (on-going) Clopidogrel + ASA v Clopidogrel <24h Early ASA v placebo studies CAPRIE (1996) ASA v Clopidogrel MATCH (2006) Clopidogrel + ASA v Clopidogrel alone FASTER (2007) <24h Clopidogrel + ASA v ASA (and simvastatin v placebo) ESPS-2 (1996) ASA v ASA-dipyridamole PRoFESS (on-going) ASA-Dipyridamole v clopidogrel (and telmisartan v placebo) ESPRIT (2007) ASA v ASA- dipyridamole CHARISMA (2006) Clopidogrel + ASA v ASA alone

  10. ASA • High dose no more effective than low dose • More side effects (bleeding) with high dose • 20-25% RRR (compared to placebo) • High quality evidence

  11. ASA v ASA+dipyridamole • ESPS-2 (1996) • ESPRIT (2006) • Verro (2008) meta-analysis of these studies plus several smaller ones • Better results with extended release • ~ 6% dropped out due to HA

  12. Clopidogrel v ASA • CAPRIE (1996) • > 19,000 patients, clopidogrel 75 vs ASA 325 daily, f/u 1-3 years • ARR of 0.51, RRR of 8.7% (favors clopidogrel) • Safety equivalent

  13. Clopidogrel-ASA v either alone • CHARISMA - (C75 + ASA) v ASA • MATCH - (ASA75 + C75) v C75 • FASTER – (ASA + C300/75) v ASA (and simvastatin v placebo) • PRoFESS – (ASA + Di) v C (Telmisartan v placebo), a study that will enroll 20,000 patients, 8,000 within the first 7 days) C = clopidogrel ASA = aspirin Di = dipyridamole

  14. MATCH double-blinded placebo-controlled trial • 7599 patients with recent ischemic stroke or TIA + 1 additional vascular risk factor • Aspirin + clopidogrel v clopidogrel alone • Primary endpoint: composite ischemic stroke, MI, vascular death, or re-hospitalization for acute ischemia (including for TIA, angina, or worsening PVD) • ARR for primary endpoint: 1% • ARI for life-threatening bleeds: 1.3% MATCH; Diener HC et al; Lancet 2004; 364: 331-337.

  15. MATCHEfficacy Safety

  16. MATCH trial patient characteristics

  17. FASTERrandomized 2x2 factorial design • 392 patients enrolled < 24hours from index event • Aspirin + clopidogrel v aspirin alone • Primary endpoint: total 90-day stroke • 7.1% with clopidogrel and aspirin • 10.8% with aspirin alone • (ARR: 3.7%, 95% CI −9.4 to 1.9, p=0·19) • 2 patients in the clopidogrel arm had ICH versus 0 in the placebo (aspirin only) arm (NS) FASTER; Kennedy, G; Lancet Neurology; 2007.

  18. FASTER v MATCH • Enrollment time window • FASTER ≤ 24 hours • MATCH < 3 months • Proportion of patients with LAA v small vessel disease • Both required AIS or TIA as qualifying event but MATCH required 1 additional risk factor • What’s being compared? • FASTER: Clopidogrel + aspirin v aspirin • MATCH: Clopidogrel + aspirin v clopidogrel

  19. Stroke Risk Depends on the Location of the Disease Rothwell PM et al. Lancet Neurology 2006;5:323–31.

  20. Anti-platelet therapyEarly intervention trials • Except for FASTER, only 2 other trials have enrolled patients “early” • IST and CAST showed a reduced recurrence of stroke and/or death in the near term (14d in IST and 30d in CAST) • ARR of about 1% when ASA given in the first 48 hrs CAST; Lancet 1997;349:1641–1649 IST; Lancet 1997; 349: 1569-1581

  21. Supporting evidence that clopidogrel + ASA helps? • EXPRESS • SOS-TIA Rothwell PM et al. Lancet 2007;370:1432-1442. Lavellee PC et al. Lancet Neurology; 2007;6:953-960.

  22. EXPRESS • Before v After method • Phase 1 (4-1-02 to 9-30-04) treatment initiated in Primary Care with appointment required to TIA clinic • Phase 2 (10-1-04 to 3-31-07) treatment initiated in TIA clinic, no appointment necessary • Nested in ongoing Oxford Vascular Study so other factors same; “before” group prospectively collected data

  23. EXPRESS • Phase 1 – 634 pts -> 310 to EXPRESS • Phase 2 – 644 pts -> 281 to EXPRESS (Other patients went directly to ED or hospital) • Baseline characteristics similar • Time to Rx – 20 days to 1 day • 90 day stroke rate – 10.3% to 2.1%

  24. EXPRESS

  25. EXPRESS

  26. EXPRESS

  27. SOS-TIA • 24 hour access hospital-based clinic for TIA patients • Assessment began ≤ 4 hours • 1-3-03 to 12-31-05, 1085 patients admitted to the clinic • Median symptom duration : 15 minutes • 53% seen ≤ 24 hours of symptom onset

  28. SOS-TIA 787 patients with definite or possible TIA

  29. SOS-TIA outcomes

  30. SOS-TIA outcomesPatients with confirmed or possible TIA • All started a stroke prevention program • 824/845 (98%) got “anti-thrombotic” meds • 43 (5%) had urgent carotid revascularization (median delay 6 days) • 44 (5%) were anticoagulated for Afib • 808 (74%) were sent home same day

  31. CEA – Faster is better For patients with ≥ 50% stenosis, the NNT to prevent 1 ipsilateral ischemic stroke was: CEA ≤ 2 weeks – 5 CEA > 12 weeks – 125 Rothwell; Lancet March 20, 2004

  32. AFib and other cardioembolic sources • Full anti-coagulation • A heparin followed up by an oral anti-coagulant

  33. Anti-platelet agents • AHA 1st line – ASA, ASA-dipyridamole or clopidogrel • ASA failure • no evidence that increasing dose helps • no evidence to switch to warfarin • ASA intolerance – use clopidogrel • Individualize

  34. Individualizing therapy • Cost • Side effects • Other co-morbidities (eg, CAD needing stent) • PRoFESS, CASTIA may give us more answers soon regarding ASA-dipyridamole v clopidogrel • Clopidogrel + ASA may work, if started early and stopped after a few months

  35. TIA in the ED – big picture • We are there 24x7 • We can begin most of the interventions • Emergency Medicine is well placed to prevent strokes in these patients

  36. Questions?www.ferne.orgjedlow@bidmc.harvard.edu ferne_clindec_2008_tia_edlow_clintrials_extended_062508_final

More Related